The ACR Government Affairs Committee has developed legislative language to limit commercial insurance plans’ cost-sharing requirements for medications in a specialty drug tier to the dollar amount applicable to drugs in the nonpreferred-brand drug tier.
Managing an In-Office Infusion Practice
The increased utilization of infusible biologics for the treatment of rheumatic diseases has opened the door for you to provide more integrated care for your patients. Having an in-office infusion center gives you the ability to deliver this service to your patients in a familiar and supportive setting.
Drug Updates: EULAR 2012
Tracking the results of drug safety and efficacy
Letter: No European Consensus on Steroid Use in Rheumatoid Arthritis
There is not a consensus between all European rheumatologists regarding the use of steroids in RA; quite a few share your skepticism, including myself.
Drug Updates
Information on new approvals and medication safety.
ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
Detailed screening and treatment recommendations based on current evidence, extensive literature review.
Minerals, Mud, Martinis, and Methylprednisone
How the practice of rheumatology differs in America and Europe.
Medication Quick Guides Offer Infusion Staff a Streamlined Resource
The ACR/ARHP Medication Quick Guides offer easily accessable pharmaceutical information to rheumatologists.
Drug Updates: Citalopram hydrobromide, Statins, and More
Information on new approvals and medication safety
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 122
- Next Page »